Article Details

After slow start, demand for COVID monoclonal antibodies treatment skyrockets

Retrieved on: 2024-04-01 17:33:34

Tags for this article:

Click the tags to see associated articles and topics

After slow start, demand for COVID monoclonal antibodies treatment skyrockets. View article details on hiswai:

Excerpt

This week, about 1,200 Houston-area patients will receive REGN-COV, a monoclonal antibody made by the drug company Regeneron of Tarrytown, New York.

Article found on: ca.movies.yahoo.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo